NetworkNewsBreaks – CytoDyn Inc.’s (CYDY) Inno
Post# of 154130
(Total Views: 173)
Posted On: 10/29/2018 4:34:28 PM
NetworkNewsBreaks – CytoDyn Inc.’s (CYDY) Innovative Anti-viral Agent Could Benefit the 36.9M Individuals Living with HIV
CytoDyn (OTCQB: CYDY), a biotechnology company, is focused on providing a treatment to the millions of people infected with the human immunodeficiency virus (HIV). A recent article discussing the company reads, “HIV targets the immune system and weakens the body’s defense systems against infections and some types of cancer. During 2017, some 1.8 million people became newly infected with HIV, bringing the global total to 36.9 million people living with HIV, according to the World Health Organization (http://nnw.fm/043wY). HIV continues to be a major public health issue, having claimed more than 35 million lives so far from every corner of the world. The market potential for PRO 140 used as an anti-viral agent in combination with a patient’s current HIV regimen (Highly Active Antiretroviral Therapy, or “HAART”) is $1.2 billion; as a monotherapy maintenance/single-drug therapy, the market is estimated at $3.8 billion.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
CytoDyn (OTCQB: CYDY), a biotechnology company, is focused on providing a treatment to the millions of people infected with the human immunodeficiency virus (HIV). A recent article discussing the company reads, “HIV targets the immune system and weakens the body’s defense systems against infections and some types of cancer. During 2017, some 1.8 million people became newly infected with HIV, bringing the global total to 36.9 million people living with HIV, according to the World Health Organization (http://nnw.fm/043wY). HIV continues to be a major public health issue, having claimed more than 35 million lives so far from every corner of the world. The market potential for PRO 140 used as an anti-viral agent in combination with a patient’s current HIV regimen (Highly Active Antiretroviral Therapy, or “HAART”) is $1.2 billion; as a monotherapy maintenance/single-drug therapy, the market is estimated at $3.8 billion.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)